CHAIRPERSONS:
David P. Carbone, Vanderbilt-Ingram Cancer Center, Nashville, TN
Roy S. Herbst, UT M. D. Anderson Cancer Center, Houston, TX
SCIENTIFIC COMMITTEE:
Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD
Elisabeth M. P. Brambilla, Hôpital A. Michallon, Cedex, France
Paul A. Bunn, Jr., University of Colorado, Aurora, CO
David P. Carbone, Vanderbilt-Ingram Cancer Center, Nashville, TN
Steven M. Dubinett, David Geffen School of Medicine at UCLA, Los Angeles, CA
Eric B. Haura, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Roy S. Herbst, UT M. D. Anderson Cancer Center, Houston, TX
Jonathan M. Kurie, UT M. D. Anderson Cancer Center, Houston, TX
Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA
Tetsuya Mitsudomi, Aichi Cancer Center Hospital, Nagoya, Japan
Kim Norris, Lung Cancer Foundation of America, Palos Verdes Estates, CA
William Pao, Vanderbilt University, Nashville, TN
Valerie W. Rusch, Memorial Sloan-Kettering Cancer Center, New York, NY
Nagahiro Saijo, National Cancer Center Hospital East, Chiba, Japan
Joan H. Schiller, UT Southwestern Medical Center, Dallas, TX
Margaret R. Spitz, UT M. D. Anderson Cancer Center, Houston, TX
Debra A. Violette, Dana-Farber Lung SPORE, Augusta, ME
Daniel D. Von Hoff, TGen, Phoenix, AZ
Ignacio I. Wistuba, UT M. D. Anderson Cancer Center, Houston, TX
This joint conference by the AACR and the IASLC will address the important issues in lung cancer research. Lung cancer kills more people than breast cancer, prostate cancer, kidney cancer, colon cancer, liver cancer, and skin cancer combined, and is the most common cause of cancer-related deaths in both men and women in the United States. Fortunately, these statistics do not tell the whole story. Thanks to research and improved detection and treatment methods, death rates for lung cancer patients, as for cancer patients overall, are declining. This meeting will discuss the important basic, translational, and clinical work that is improving lung cancer prevention, detection, and treatment. The conference will begin with a Keynote Lecture from Tyler Jacks, President of the AACR and Director of the David H. Koch Institute for Integrative Cancer Research at MIT. Additional topics to be covered include drug design, target identification, early detection, cancer stem cells, microRNAs, genome wide approaches to determining risk and outcome, mouse models, and the tumor microenvironment. The role of cancer advocacy in supporting research will also be an important aspect of this meeting. The AACR and IASLC have designed this conference to promote the advancement of knowledge about lung cancer and the development of novel prevention, early detection, and treatment strategies for it.